

DAFTAR PUSTAKA

- Azim, H. A. J., & Partridge, A. H. (2014). Biology of breast cancer in young women. *Breast Cancer Research, 16*(4), 427. <https://doi.org/10.1186/s13058-014-0427-5>
- Baghban, R., Roshangar, L., Jahanban-Esfahlan, R., Seidi, K., Ebrahimi-Kalan, A., Jaymand, M., Kolahian, S., Javaheri, T., & Zare, P. (2020). Tumor microenvironment complexity and therapeutic implications at a glance. *Cell Communication and Signaling, 18*(1), 59. <https://doi.org/10.1186/s12964-020-0530-4>
- Banerjee, K., Kerzel, T., Bekkhus, T., de Souza Ferreira, S., Wallmann, T., Wallerius, M., Landwehr, L.-S., Agardy, D. A., Schauer, N., Malmerfeldt, A., Bergh, J., Bartish, M., Hartman, J., Östman, A., Squadrito, M. L., & Rolny, C. (2023). VEGF-C-expressing TAMs rewire the metastatic fate of breast cancer cells. *Cell Reports, 42*(12), 113507. <https://doi.org/10.1016/j.celrep.2023.113507>
- Banerjee, S., Thomas, A., & Daly, R. (2023a). Macrophage-mediated lymphatic remodeling in cancer progression. *Nature Communications, 14*, 345. <https://doi.org/10.1038/s41467-023-38910-5>
- Banerjee, S., Thomas, A., & Daly, R. (2023b). Tumor-associated macrophages drive lymphangiogenesis and metastasis. *Nature Communications, 14*, 345. <https://doi.org/10.1038/s41467-023-38910-5>
- Brogowska, K., Kowalski, P., & Nowak, A. (2023). Molecular regulation of lymphatic endothelial development. *Cells, 12*(4), 655. <https://doi.org/10.3390/cells12040655>
- CDC. (n.d.). *What Is Breast Cancer?* . 2023. Retrieved March 9, 2024, from https://www.cdc.gov/cancer/breast/basic_info/what-is-breast-cancer.htm
- Chaudhary, L. N., Wilkinson, K. H., & Kong, A. (2018). Triple-Negative Breast Cancer: Who Should Receive Neoadjuvant Chemotherapy? In *Surgical Oncology Clinics of North America* (Vol. 27, Issue 1, pp. 141–153). W.B. Saunders. <https://doi.org/10.1016/j.soc.2017.08.004>
- Chen, J.-Y., Lai, Y.-S., Chu, P.-Y., Chan, S.-H., Wang, L.-H., & Hung, W.-C. (2019). Cancer-Derived VEGF-C Increases Chemokine Production in Lymphatic Endothelial Cells to Promote CXCR2-Dependent Cancer Invasion and MDSC Recruitment. *Cancers, 11*(8), 1120. <https://doi.org/10.3390/cancers11081120>
- Chen, L., Xu, J., & Zhao, S. (2021). Pre-metastatic niche formation in lymph nodes. *Nature Reviews Clinical Oncology, 18*(3), 175–193. <https://doi.org/10.1038/s41571-020-00442-x>
- D. Radosavljevic, G., Pantic, J., Simovic Markovic, B., & Arsenijevic, N. (2022). Modulators of Tumor Angiogenesis: Insights into the Role of Galectin-3 and IL-17 Signaling. In *Tumor Angiogenesis and Modulators*. IntechOpen. <https://doi.org/10.5772/intechopen.102893>
- Dieterich, L. C., & Detmar, M. (2022a). Tumor lymphangiogenesis and metastatic spread. *Oncogene, 41*, 193–208. <https://doi.org/10.1038/s41388-021-02060-2>

- Dieterich, L. C., & Detmar, M. (2022b). Tumor lymphangiogenesis: molecular mechanisms and clinical implications. *Oncogene*, *41*, 193–208. <https://doi.org/10.1038/s41388-021-02060-2>
- Eroğlu, A., Ersöz, C., Karasoy, D., & Sak, S. (2017). Vascular endothelial growth factor (VEGF)-C, VEGF-D, VEGFR-3 and D2-40 expressions in primary breast cancer: Association with lymph node metastasis. *Advances in Clinical and Experimental Medicine : Official Organ Wroclaw Medical University*, *26*(2), 245–249. <https://doi.org/10.17219/acem/58784>
- Feng, Y., Spezia, M., Huang, S., Yuan, C., Zeng, Z., Zhang, L., Ji, X., Liu, W., Huang, B., & Luo, W. (2018). Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. *Genes & Diseases*, *5*(2), 77–106.
- Ferrari, G., Cook, B. D., Terushkin, V., Pintucci, G., & Mignatti, P. (2009). Transforming growth factor-beta 1 (TGF- β 1) induces angiogenesis through vascular endothelial growth factor (VEGF)-mediated apoptosis. *Journal of Cellular Physiology*, *219*(2), 449–458.
- Francies, F. Z., Hull, R., Khanyile, R., & Dlamini, Z. (2020). Breast cancer in low-middle income countries: abnormality in splicing and lack of targeted treatment options. *American Journal of Cancer Research*, *10*(5), 1568.
- Frisca, S. C. T., & Sandra, F. (2009). Angiogenesis: patofisiologi dan aplikasi klinis. *JKM*, *8*(2), 174–187.
- He, Y., Rajantie, I., Pajusola, K., Jeltsch, M., Holopainen, T., Yla-Herttuala, S., Harding, T., Jooss, K., Takahashi, T., & Alitalo, K. (2005). Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. *Cancer Research*, *65*(11), 4739–4746. <https://doi.org/10.1158/0008-5472.CAN-04-4576>
- Hoshida, T., Isaka, N., Hagedoorn, J., di Tomaso, E., Chen, Y.-L., Pytowski, B., Fukumura, D., Padera, T. P., & Jain, R. K. (2006). Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications. *Cancer Research*, *66*(16), 8065–8075. <https://doi.org/10.1158/0008-5472.CAN-06-1392>
- Hossain, M., Rahman, T., & Kim, S. (2024). Epithelial-mesenchymal transition and lymphatic spread in breast cancer. *Cancers*, *16*(2), 512. <https://doi.org/10.3390/cancers16020512>
- Huang, Y., Li, Q., & Chen, Y. (2022). Peritumoral lymphatics as major conduits for metastasis. *Frontiers in Oncology*, *12*, 887654. <https://doi.org/10.3389/fonc.2022.887654>
- Huang, Y.-H., Yang, H.-Y., Huang, S.-W., Ou, G., Hsu, Y.-F., & Hsu, M.-J. (2016). Interleukin-6 Induces Vascular Endothelial Growth Factor-C Expression via Src-FAK-STAT3 Signaling in Lymphatic Endothelial Cells. *PLOS ONE*, *11*(7), e0158839. <https://doi.org/10.1371/journal.pone.0158839>
- Indra, Manginstar, C., Islam, A. A., Sampepajung, D., Hamdani, W., Bukhari, A., Syamsu, S. A., Prihantono, Smaradania, N., & Faruk, M. (2021). The relationship between NF κ B, HER2, ER expression and anthracycline -based

- neoadjuvan chemotherapy response in local advanced stadium breast cancer: A cohort study in Eastern Indonesia. *Annals of Medicine and Surgery*, 63, 102164. <https://doi.org/10.1016/j.amsu.2021.02.010>
- Jenmbacken, K., Vallbo, C., Wang, W., & Damber, J.-E. (2005). Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis. *The Prostate*, 65(2), 110–116. <https://doi.org/10.1002/pros.20276>
- Jha, S. K., Rauniyar, K., Karpanen, T., Leppänen, V.-M., Brouillard, P., Vikkula, M., Alitalo, K., & Jeltsch, M. (2017). Efficient activation of the lymphangiogenic growth factor VEGF-C requires the C-terminal domain of VEGF-C and the N-terminal domain of CCBE1. *Scientific Reports*, 7(1), 4916.
- Johns, S. C., Yin, X., Jeltsch, M., Bishop, J. R., Schuksz, M., El Ghazal, R., Wilcox-Adelman, S. A., Alitalo, K., & Fuster, M. M. (2016). Functional importance of a proteoglycan coreceptor in pathologic lymphangiogenesis. *Circulation Research*, 119(2), 210–221.
- Kementerian Kesehatan RI. (2018). *Hasil Riset Kesehatan Dasar (Riskesdas) 2018*. .
- Kola, B., Kakkat, S., Suman, P., Crouch, E., Chakroborty, D., & Sarkar, C. (2025). Lymphangiogenesis in Breast Cancer: From Molecular Mechanisms to Clinical Implications. *FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology*, 39(9), e70590. <https://doi.org/10.1096/fj.202500024R>
- KPKN-Komite Penanggulangan Kanker Nasional. (2015). *Panduan Nasional Penanganan Kanker: Kanker Payudara*.
- Kresno, S. B. (2011). Micro-RNA dan implikasinya pada kanker. *Indonesian Journal of Cancer*, 5(3).
- Lester, S. C. (2010). *Manual of Surgical Pathology: Expert Consult-Online and print*. Elsevier Health Sciences.
- Liu, G., Chen, X.-T., Zhang, H., & Chen, X. (2022). Expression analysis of cytokines IL-5, IL-6, IL-8, IL-17 and VEGF in breast cancer patients. *Frontiers in Oncology*, 12. <https://doi.org/10.3389/fonc.2022.1019247>
- Łukasiewicz, S., Czezelewski, M., Forma, A., Baj, J., Sitarz, R., & Stanisławek, A. (2021). Breast cancer—epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—an updated review. *Cancers*, 13(17), 4287.
- Madu, C. O., Wang, S., Madu, C. O., & Lu, Y. (2020). Angiogenesis in Breast Cancer Progression, Diagnosis, and Treatment. *Journal of Cancer*, 11(15), 4474–4494. <https://doi.org/10.7150/jca.44313>
- Manuel García-Castellano, J., García-Padrón, D., Martínez-Aragón, N., Ramírez-Sánchez, M., Vera-Gutiérrez, V., & Fernández-Pérez, L. (2022). Role of the IL-6/Jak/Stat Pathway in Tumor Angiogenesis: Influence of Estrogen Status. In *Tumor Angiogenesis and Modulators*. IntechOpen. <https://doi.org/10.5772/intechopen.104102>
- Masood, S. (1995). Prognostic factors in breast cancer: use of cytologic preparations. *Diagnostic Cytopathology*, 13(5), 388–395.

- Matsumoto, M., Roufail, S., Inder, R., Caesar, C., Karnezis, T., Shayan, R., Farnsworth, R. H., Sato, T., Achen, M. G., Mann, G. B., & Stacker, S. A. (2013). Signaling for lymphangiogenesis via VEGFR-3 is required for the early events of metastasis. *Clinical & Experimental Metastasis*, 30(6), 819–832. <https://doi.org/10.1007/s10585-013-9581-x>
- Melincovici, C. S., Boşca, A. B., Şuşman, S., Mărginean, M., Mişu, C., Istrate, M., Moldovan, I. M., Roman, A. L., & Mişu, C. M. (2018). Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis. *Romanian Journal of Morphology and Embryology = Revue Roumaine de Morphologie et Embryologie*, 59(2), 455–467.
- Milovanović, J., Vujašinović, T., Todorović-Raković, N., Greenman, J., Hranisavljević, J., & Radulović, M. (2023). Vascular endothelial growth factor (VEGF)-A,-C and VE-cadherin as potential biomarkers in early breast cancer patients. *Pathology-Research and Practice*, 252, 154923.
- Muz, B., de la Puente, P., Azab, F., & Kareem Azab, A. (2015). The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. *Hypoxia*, 83–92.
- Nakamura, Y., Yasuoka, H., Tsujimoto, M., Yoshidome, K., Nakahara, M., Nakao, K., Nakamura, M., & Kakudo, K. (2006). Nitric oxide in breast cancer: induction of vascular endothelial growth factor-C and correlation with metastasis and poor prognosis. *Clinical Cancer Research : An Official Journal of the American Association for Cancer Research*, 12(4), 1201–1207. <https://doi.org/10.1158/1078-0432.CCR-05-1269>
- Naoum, G. E., Roberts, S., Brunelle, C. L., Shui, A. M., Salama, L., Daniell, K., Gillespie, T., Bucci, L., Smith, B. L., & Ho, A. Y. (2020). Quantifying the impact of axillary surgery and nodal irradiation on breast cancer-related lymphedema and local tumor control: long-term results from a prospective screening trial. *Journal of Clinical Oncology*, 38(29), 3430.
- Okano, H., Onmori, R., Tomita, N., & Ikada, Y. (2006). Effects of a moderate-intensity static magnetic field on VEGF-A stimulated endothelial capillary tubule formation in vitro. *Bioelectromagnetics: Journal of the Bioelectromagnetics Society, The Society for Physical Regulation in Biology and Medicine, The European Bioelectromagnetics Association*, 27(8), 628–640.
- Ortiz de Solorzano, C., Chin, K., Gray, J. W., & Lockett, S. J. (2003). *In situ quantification of genomic instability in breast cancer progression*. Lawrence Berkeley National Lab.(LBNL), Berkeley, CA (United States).
- Petrucelli, N., Daly, M. B., & Pal, T. (2022). *BRCA1-and BRCA2-associated hereditary breast and ovarian cancer*.
- Pranoto, A. S., Haryasena, H., Prihantono, P., Rahman, S., Sampepajung, D., Indra, I., Syamsu, S. A., Sampepajung, E., Nelwan, B. J., & Faruk, M. (2021). The expression of programmed death-ligand 1 and its association with histopathological grade, stage of disease, and occurrence of metastasis in breast cancer. *Breast Disease*, 40(s1), S71–S76. <https://doi.org/10.3233/BD-219010>

- Prihantono, & Faruk, M. (2023). Neoadjuvant chemotherapy response, disease-free survival, and overall survival of breast cancer in a single institution. *Surgery Open Science*, *15*, 19–25. <https://doi.org/10.1016/j.sopen.2023.07.016>
- Rauniyar, K., Jha, S. K., & Jeltsch, M. (2018). Biology of vascular endothelial growth factor C in the morphogenesis of lymphatic vessels. *Frontiers in Bioengineering and Biotechnology*, *6*, 7.
- Ronca, R., Benkheil, M., Mitola, S., Struyf, S., & Liekens, S. (2017). Tumor angiogenesis revisited: Regulators and clinical implications. *Medicinal Research Reviews*, *37*(6), 1231–1274.
- Rosen, E. M., Ma, Y., & Fan, S. (2008). BRCA1 cross-talk with hormone receptors. In *Hormone Receptors in Breast Cancer* (pp. 1–20). Springer.
- Semenza, G. L. (2012). Hypoxia-inducible factors in physiology and medicine. *Cell*, *148*(3), 399–408. <https://doi.org/10.1016/j.cell.2012.01.021>
- Setia, M. S. (2016). Methodology series module 3: Cross-sectional studies. *Indian Journal of Dermatology*, *61*(3), 261–264. <https://doi.org/10.4103/0019-5154.182410>
- Shivakumar, S., Prabhakar, B. T., Jayashree, K., Rajan, M. G. R., & Salimath, B. P. (2009). Evaluation of serum vascular endothelial growth factor (VEGF) and microvessel density (MVD) as prognostic indicators in carcinoma breast. *Journal of Cancer Research and Clinical Oncology*, *135*(4), 627–636. <https://doi.org/10.1007/s00432-008-0497-9>
- Skobe, M., Hawighorst, T., Jackson, D. G., Prevo, R., Janes, L., Velasco, P., Riccardi, L., Alitalo, K., Claffey, K., & Detmar, M. (2001). Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. *Nature Medicine*, *7*(2), 192–198. <https://doi.org/10.1038/84643>
- Skoog, P., Ohlsson, M., Fernö, M., Ryden, L., Borrebaeck, C. A. K., & Wingren, C. (2017). Tumor tissue protein signatures reflect histological grade of breast cancer. *PloS One*, *12*(6), e0179775.
- Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*, *71*(3), 209–249.
- WHO. (2020). Cancer incident in Indonesia. *IARC*, *858*, 1-2.
- WHO. (2023). *Breast cancer*. <https://www.who.int/news-room/fact-sheets/detail/breast-cancer>
- Zhang, B.-N., Cao, X.-C., Chen, J.-Y., Chen, J., Fu, L., Hu, X.-C., Jiang, Z.-F., Li, H.-Y., Liao, N., & Liu, D.-G. (2012). Guidelines on the diagnosis and treatment of breast cancer (2011 edition). *Gland Surgery*, *1*(1), 39.
- Zhang, S., Yi, S., Zhang, D., Gong, M., Cai, Y., & Zou, L. (2017). Intratumoral and peritumoral lymphatic vessel density both correlate with lymph node metastasis in breast cancer. *Scientific Reports*, *7*(1), 40364. <https://doi.org/10.1038/srep40364>
- Zhang, W., Zhao, L., & Liu, J. (2020). Serum VEGF-C levels and lymph node metastasis in breast cancer: A meta-analysis. *BMC Cancer*, *20*, 7180. <https://doi.org/10.1186/s12885-020-07180-4>

- Zhang, Z., Luo, G., Tang, H., Cheng, C., Wang, P., Liu, X., & Peng, Y. (2016). Prognostic significance of high VEGF-C expression for patients with breast cancer: an updated meta-analysis. *PLOS ONE*, *11*(11), e0165725. <https://doi.org/10.1371/journal.pone.0165725>
- Zhao, Y.-C., Ni, X.-J., Li, Y., Dai, M., Yuan, Z.-X., Zhu, Y.-Y., & Luo, C.-Y. (2012). Peritumoral lymphangiogenesis induced by vascular endothelial growth factor C and D promotes lymph node metastasis in breast cancer patients. *World Journal of Surgical Oncology*, *10*, 165. <https://doi.org/10.1186/1477-7819-10-165>
- Zhu, H., & Doğan, B. E. (2021). American Joint Committee on Cancer's Staging System for Breast Cancer, Eighth Edition: Summary for Clinicians. *European Journal of Breast Health*, *17*(3), 234–238. <https://doi.org/10.4274/ejbh.galenos.2021.2021-4-3>
- Ziemer, L. S., Koch, C. J., Maity, A., Magarelli, D. P., Horan, A. M., & Evans, S. M. (2001). Hypoxia and VEGF mRNA expression in human tumors. *Neoplasia*, *3*(6), 500–508.

NAMA	USIA	Grading Histopatologi	STADIUM KANKI	METASTASIS KGB	METASTASIS JAUH	LOKASI META	Kadar VEGF-C2
HJ SURIANI	47	grade 3	MBC	POSITIF	POSITIF	POSITIF PAR	984.49
NAHDIAH	51	Grade 3	MBC	POSITIF	POSITIF	PARU-PARU	6037.91
MUKRIANI	42	Grade 3	MBC	POSITIF	POSITIF	HEPAR	6014.22
SUARTINA	28	Grade 2	MBC	POSITIF	POSITIF	PARU-PARU	14390.965
ROSNAINI	47	Grade 3	MBC	POSITIF	POSITIF	PARU-PARU	2334.478
KUSMAWATI	53	Grade 3	MBC	POSITIF	POSITIF	VERTEBRA	2480.49
SERIANI	45	Grade 3	MBC	POSITIF	POSITIF	HEPAR	891.155
HAMSI AH T	59	Grade 2	MBC	POSITIF	POSITIF	PARU-PARU	922.07
SUMARNI	42	Grade 2	MBC	POSITIF	POSITIF	PARU-PARU	4024.39
NURSYAMSI D	54	grade 3	MBC	POSITIF	POSITIF	PARU-PARU	4148.945
ISTI LUSIANTI	32	grade 3	MBC	POSITIF	POSITIF	PARU-PARU	983.445
KARTINI	57	grade 3	MBC	POSITIF	POSITIF	PARU-PARU	2928.83
HARIYANA	38	grade 2	MBC	POSITIF	POSITIF	PARU-PARU	559.744
HERMAWATI	41	grade 2	MBC	POSITIF	POSITIF	HEPAR	1428.31
USNIARTI	51	grade 3	MBC	POSITIF	POSITIF	PARU-PARU	828.84
NURDIATI	49	grade 2	MBC	POSITIF	POSITIF	HEPAR	1428.31
YOANDA KR IS	50	grade 2	MBC	POSITIF	POSITIF	OTAK	813.155
MARAWIA	41	grade 3	MBC	POSITIF	POSITIF	HEPAR	521.63
ERNI	41	grade 2	MBC	POSITIF	POSITIF	PARU-PARU	702.01
QAMARIAH	46	grade 3	MBC	POSITIF	POSITIF	PARU-PARU	734.02
KAMANNENG	69	grade 1	LABC	NEGATIF	NEGATIF	TIDAK	536.476
RATNA	49	grade 3	EBC	NEGATIF	NEGATIF	TIDAK	734.02
ROSDIANA	40	grade 2	LABC	NEGATIF	NEGATIF	TIDAK	538.375
NURLISA O MA	46	grade 3	LABC	NEGATIF	NEGATIF	TIDAK	1164.355
SYAMSIANA	48	grade 1	EBC	NEGATIF	NEGATIF	TIDAK	1194.09
FIFI ERFIANI	39	grade 3	LABC	NEGATIF	POSITIF	TIDAK	571.64
ROSA KURNIAH	52	grade 3	EBC	NEGATIF	NEGATIF	TIDAK	1179.235
SITTI HASNIAH	44	grade 3	EBC	NEGATIF	NEGATIF	TIDAK	555.045
WIDYAWATI	46	grade 1	MBC	POSITIF	POSITIF	VERTEBRA	235.266
ASMAWATY	36	grade 1	MBC	POSITIF	POSITIF	VERTEBRA	6167.98
MUNIRA	52	grade 2	LABC	NEGATIF	NEGATIF	TIDAK	1029.105
SUNDARI SAH	67	grade 1	MBC	POSITIF	POSITIF	PARU-PARU	860.08
FASIHA A. MA	66	grade 1	MBC	POSITIF	POSITIF	PARU-PARU	1756.555
SANCI LETLOR	36	grade 1	EBC	NEGATIF	NEGATIF	TIDAK	1282.65
WAHIDA	48	grade 3	MBC	POSITIF	POSITIF	VERTEBRA	1428.5
YANTI TANDIA	46	grade 2	EBC	NEGATIF	NEGATIF	TIDAK	487.89
ANI	46	grade 3	EBC	NEGATIF	NEGATIF	TIDAK	110.578
DARSIPA	53	grade 1	EBC	NEGATIF	NEGATIF	TIDAK	937.47
SUMARNI	49	grade 1	LABC	NEGATIF	NEGATIF	TIDAK	1298.325
ROHANA TOM	64	grade 1	EBC	NEGATIF	NEGATIF	TIDAK	937.47
NURMIATI	36	grade 3	LABC	NEGATIF	NEGATIF	TIDAK	968.155
WAODE AMALI	37	grade 2	LABC	NEGATIF	POSITIF	TIDAK	313.03
BONDENG	76	grade 1	EBC	NEGATIF	NEGATIF	TIDAK	1384.85
GUSNIATI	41	grade 3	EBC	NEGATIF	NEGATIF	TIDAK	781.645
JUMRAH H K	45	grade 2	MBC	POSITIF	POSITIF	VERTEBRA	553.94
BAHIRAH	52	grade 2	EBC	NEGATIF	NEGATIF	TIDAK	983.445
KARDINA HUS	41	grade 3	LABC	NEGATIF	NEGATIF	TIDAK	331.08
DARNISA	55	grade 1	LABC	NEGATIF	POSITIF	TIDAK	1399.36
WELHELMINA	61	grade 2	LABC	NEGATIF	POSITIF	TIDAK	3861.685
AGUSTIN FIT	53	grade 2	EBC	NEGATIF	NEGATIF	TIDAK	1770.57
SUNARTI	49	grade 2	LABC	NEGATIF	NEGATIF	TIDAK	1194.09
HASMAH	56	grade 3	LABC	NEGATIF	NEGATIF	TIDAK	571.64
HASNIATI	54	grade 3	LABC	NEGATIF	NEGATIF	TIDAK	524.788
RADEN ENY YU	43	grade 2	EBC	NEGATIF	NEGATIF	TIDAK	952.83

Titik Koordinat Kadar VEGF-C

Positive if Greater Than or Equal To	Sensitivity	1 - Specificity
110.578	1.000	1.000
235.266	1.000	0.967
313.030	0.958	0.967
521.630	0.958	0.867
524.788	0.917	0.867
559.744	0.917	0.700
571.640	0.875	0.700
702.010	0.875	0.633
734.020	0.833	0.633
781.645	0.792	0.600
813.155	0.792	0.567
860.080	0.708	0.567
891.155	0.708	0.533
937.470	0.625	0.533
952.830	0.625	0.467
983.445	0.625	0.400
984.490	0.583	0.367
1029.105	0.542	0.367
1194.090	0.542	0.267
1282.650	0.542	0.200
1428.310	0.542	0.067
1756.555	0.458	0.067
1770.570	0.417	0.067
2334.478	0.417	0.033

3861.685	0.292	0.033
4024.390	0.292	0.000
14390.965	0.042	0.000
14391.965	0.000	0.000